Related Experiment Video
Updated: Dec 27, 2025
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
A New NT4 Peptide-Based Drug Delivery System for Cancer Treatment
Jlenia Brunetti1, Sara Piantini2, Marco Fragai3
1Department of Medical Biotechnology, University of Siena, via Aldo Moro 2, 53100 Siena, Italy.
Abstract:
The development of selective tumor targeting agents to deliver multiple units of chemotherapy drugs to cancer tissue would improve treatment efficacy and greatly advance progress in cancer therapy. Here we report a new drug delivery system based on a tetrabranched peptide known as NT4, which is a promising cancer theranostic by virtue of its high cancer selectivity. We developed NT4 directly conjugated with one, two, or three units of paclitaxel and an NT4-based nanosystem, using NIR-emitting quantum dots, loaded with the NT4 tumor-targeting agent and conjugated with paclitaxel, to obtain a NT4-QD-PTX nanodevice designed to simultaneously detect and kill tumor cells. The selective binding and in vitro cytotoxicity of NT4-QD-PTX were higher than for unlabeled QD-PTX when tested on the human colon adenocarcinoma cell line HT-29. NT4-QD-PTX tumor-targeted nanoparticles can be considered promising for early tumor detection and for the development of effective treatments combining simultaneous therapy and diagnosis.
Insights
A novel NT4-based nanodevice (NT4-QD-PTX) demonstrates high selectivity for cancer cells, enabling simultaneous tumor detection and chemotherapy delivery. This targeted approach enhances treatment efficacy and advances cancer therapy.
Area of Science:
- Nanotechnology in oncology
- Bioconjugate chemistry
- Cancer theranostics
Background:
- Current cancer therapies face challenges with drug delivery and tumor selectivity.
- Developing targeted agents is crucial for improving treatment efficacy and reducing side effects.
- Theranostics offer a dual approach for simultaneous diagnosis and therapy.
Purpose of the Study:
- To develop a novel drug delivery system for targeted cancer therapy.
- To create an NT4-based nanodevice for simultaneous tumor detection and chemotherapy.
- To evaluate the efficacy and selectivity of the NT4-QD-PTX nanodevice.
Main Methods:
- Conjugation of paclitaxel (PTX) to a tetrabranched peptide NT4.
- Development of an NT4-based nanosystem incorporating quantum dots (QD) and PTX (NT4-QD-PTX).
- In vitro assessment of NT4-QD-PTX selective binding and cytotoxicity on HT-29 cells.
Main Results:
- NT4-QD-PTX nanodevices were successfully synthesized, targeting cancer cells selectively.
- The NT4-QD-PTX system exhibited enhanced selective binding compared to unlabeled QD-PTX.
- In vitro studies showed higher cytotoxicity for NT4-QD-PTX on HT-29 cells.
Conclusions:
- NT4-QD-PTX nanoparticles represent a promising platform for targeted cancer therapy and early detection.
- The developed nanodevice facilitates simultaneous tumor imaging and drug delivery.
- This approach holds potential for advancing combined diagnostic and therapeutic strategies in oncology.
Related Concept Videos
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...